Point mutations abolish 11 beta-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess.

Ferrari P, Obeyesekere VR, Li K, Wilson RC, New MI, Funder JW, Krozowski ZS

Open source

DOI
10.1016/0303-7207(96)03787-2
Published
1996 May 17
Container
Molecular and cellular endocrinology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/0303-7207-96-03787-2,
  title = {Point mutations abolish 11 beta-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess.},
  author = {Ferrari P and Obeyesekere VR and Li K and Wilson RC and New MI and Funder JW and Krozowski ZS},
  year = {1996},
  journal = {Molecular and cellular endocrinology},
  doi = {10.1016/0303-7207(96)03787-2},
  url = {https://doi.org/10.1016/0303-7207(96)03787-2}
}

RIS

TY  - JOUR
TI  - Point mutations abolish 11 beta-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess.
AU  - Ferrari P
AU  - Obeyesekere VR
AU  - Li K
AU  - Wilson RC
AU  - New MI
AU  - Funder JW
AU  - Krozowski ZS
PY  - 1996
JO  - Molecular and cellular endocrinology
DO  - 10.1016/0303-7207(96)03787-2
UR  - https://doi.org/10.1016/0303-7207(96)03787-2
ER  - 

APA

P, F., VR, O., K, L., RC, W., MI, N., JW, F., & ZS, K. (1996). Point mutations abolish 11 beta-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess.. Molecular and cellular endocrinology. https://doi.org/10.1016/0303-7207(96)03787-2

Source records